GRI Bio
Clinical-stage biopharmaceutical company developing small-molecule modulators of Natural Killer T (NKT) cells to treat inflammatory, fibrotic and autoimmune diseases. The company advances lead oral small-molecule programs targeting invariant NKT (iNKT) inhibition for idiopathic pulmonary fibrosis and type 2 NKT activation for systemic lupus erythematosus, and maintains a proprietary compound library to support pipeline expansion. Activities include preclinical studies, biomarker-driven clinical trials, regulatory filings (IND, orphan designation) and patent prosecution.
Industries
Nr. of Employees
small (1-50)
GRI Bio
Patents
Oxygenated and amino- or ammonium-containing phosphonic acid derivatives and their medical use
US-12528775-B2
View DetailsOxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
US-11453642-B2
View Details
Oxygenated and amino- or ammonium-containing phosphonic acid derivatives and their medical use
US-12528775-B2
View DetailsOxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
US-11453642-B2
View DetailsProducts
Oral iNKT antagonist program for idiopathic pulmonary fibrosis (lead clinical program)
Development of an orally administered small-molecule inhibitor of invariant NKT cell activity for treatment of idiopathic pulmonary fibrosis; advanced to Phase 2a biomarker study with PK/PD and safety endpoints.
Type 2 NKT activator program for systemic lupus erythematosus (development program)
Development of an oral small-molecule activator of Type 2 NKT cells designed to modulate autoimmune responses with an initial focus on systemic lupus erythematosus; undergoing IND-enabling activities toward Phase 1.
Oral iNKT antagonist program for idiopathic pulmonary fibrosis (lead clinical program)
Development of an orally administered small-molecule inhibitor of invariant NKT cell activity for treatment of idiopathic pulmonary fibrosis; advanced to Phase 2a biomarker study with PK/PD and safety endpoints.
Type 2 NKT activator program for systemic lupus erythematosus (development program)
Development of an oral small-molecule activator of Type 2 NKT cells designed to modulate autoimmune responses with an initial focus on systemic lupus erythematosus; undergoing IND-enabling activities toward Phase 1.
Expertise Areas
- NKT cell immunomodulation
- Clinical trial management (Phase 1–2a)
- Biomarker and immune profiling
- Pharmacokinetics / pharmacodynamics
Key Technologies
- Small-molecule NKT modulators
- Biomarker assays (serum and BAL)
- Immune cell profiling
- Gene expression analysis
News & Updates
Corporate presentation describing company strategy and pipeline.
Regulatory designation awarded for lead iNKT antagonist program for idiopathic pulmonary fibrosis.
First quarter 2026 results reported alongside clinical data reinforcing differentiated profile of lead program in IPF.
Issued notice of allowance for patent application covering type 2 NKT agonists for inflammatory conditions.
U.S. FDA cleared IND for lead iNKT antagonist program; Phase 2a biomarker study design and timelines described.
Canadian Intellectual Property Office issued notice of allowance for patent application covering compositions and methods for modulating NKT cells for inflammatory conditions.
Corporate presentation describing company strategy and pipeline.
Regulatory designation awarded for lead iNKT antagonist program for idiopathic pulmonary fibrosis.
First quarter 2026 results reported alongside clinical data reinforcing differentiated profile of lead program in IPF.
Issued notice of allowance for patent application covering type 2 NKT agonists for inflammatory conditions.
U.S. FDA cleared IND for lead iNKT antagonist program; Phase 2a biomarker study design and timelines described.
Canadian Intellectual Property Office issued notice of allowance for patent application covering compositions and methods for modulating NKT cells for inflammatory conditions.